12月4日 - ** 新月生物制药CBIO.O股价盘前上涨36.5%至18.30美元
** 公司称已与中国科伦生物技术公司建立独家合作伙伴关系，共同开发和销售新型癌症治疗药物
** 公司还将向投资者募集 1.85 亿美元，用于资助临床试验 - CBIO
** 凯伦生物技术公司获得了该公司实验药物CR-001在大中华区的销售权。
** CBIO的CR-001旨在增强免疫反应和阻断肿瘤的血液供应；SKB105针对实体瘤。
** 两家公司都计划对药物进行单独和联合试验；公司表示，将于2026年对3种药物进行人体试验
** 截至上一交易日收盘，股价年累计下跌约 46
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.